4516 Share Price Performance
Recent 4516 News & Updates
No updates
Nippon Shinyaku Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 07, 2025
- Earnings per share (EPS)
- 483.21
- Gross Margin
- 68.10%
- Net Profit Margin
- 20.32%
- Debt/Equity Ratio
- 0%
Nippon Shinyaku Co., Ltd. Competitors
About 4516
- Founded
- 1911
- Employees
- 2243
- CEO
- WebsiteView website
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and RGX-121 for the treatment of mucopolysaccharidosis. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Japanese Market Performance
- 7 Days: -1.0%
- 3 Months: 9.0%
- 1 Year: 9.0%
- Year to Date: 7.0%
The market has been flat over the last week. As for the longer term, the market has risen 9.0% in the past 12 months. As for the next few years, earnings are expected to grow by 7.8% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading